Novo Nordisk licenses Adimab discovery platform, custom library
This article was originally published in Scrip
Executive Summary
Adimab announced its third technology transfer agreement this year, expanding an established antibody discovery partnership with Novo Nordisk following similar deals with GlaxoSmithKline and Biogen Idec in July (scripintelligence.com,27 July 2013).